Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP)

Trial Profile

Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP)

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Thrombocytopenia
  • Focus Registrational; Therapeutic Use
  • Sponsors GC Pharma; Green Cross
  • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 23 May 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top